AllianceBernstein’s iTeos Therapeutics ITOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-44,180
Closed -$440K 3274
2025
Q2
$440K Buy
44,180
+11,670
+36% +$94K ﹤0.01% 2719
2025
Q1
$194K Hold
32,510
﹤0.01% 2929
2024
Q4
$250K Hold
32,510
﹤0.01% 2959
2024
Q3
$332K Sell
32,510
-5,900
-15% -$90K ﹤0.01% 2870
2024
Q2
$570K Buy
38,410
+6,580
+21% +$94.3K ﹤0.01% 2606
2024
Q1
$434K Sell
31,830
-3,490
-10% -$38K ﹤0.01% 2641
2023
Q4
$387K Hold
35,320
﹤0.01% 2731
2023
Q3
$387K Sell
35,320
-1,740
-5% -$22.3K ﹤0.01% 2704
2023
Q2
$491K Buy
37,060
+11,760
+46% +$168K ﹤0.01% 2648
2023
Q1
$344K Sell
25,300
-3,622
-13% -$64.9K ﹤0.01% 2719
2022
Q4
$565K Sell
28,922
-43,857
-60% -$857K ﹤0.01% 2565
2022
Q3
$1.39M Sell
72,779
-558,339
-88% -$12.9M ﹤0.01% 2118
2022
Q2
$13M Sell
631,118
-486,228
-44% -$11.5M 0.01% 1011
2022
Q1
$36M Sell
1,117,346
-187,867
-14% -$6.83M 0.01% 703
2021
Q4
$60.8M Sell
1,305,213
-29,868
-2% -$994K 0.02% 564
2021
Q3
$36M Sell
1,335,081
-19,997
-1% -$523K 0.01% 723
2021
Q2
$34.8M Buy
1,355,078
+185,077
+16% +$4.41M 0.01% 732
2021
Q1
$40M Buy
1,170,001
+71,901
+7% +$2.6M 0.02% 684
2020
Q4
$37.1M Buy
1,098,100
+330,016
+43% +$8.74M 0.02% 671
2020
Q3
$18.9M Buy
+768,084
New +$20.7M 0.01% 819

Other funds holding ITOS

AllianceBernstein's ITOS Position: Q3 2025 in Review

AllianceBernstein sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 44,180 shares — an estimated $440K sold.

AllianceBernstein first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $60.8M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • AllianceBernstein reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AllianceBernstein sold 44,180 iTeos Therapeutics shares in Q3 2025, an estimated $440K.
  • AllianceBernstein first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
  • AllianceBernstein's iTeos Therapeutics position peaked at $60.8M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on AllianceBernstein's 13F filing for Q3 2025, filed 14 Nov 2025.